Wuhan Ruijian Pharmaceuticals Secures Tens of Millions in Pre-A Funding Led by Renfu Industrial Fund and HuaFang Capital

Wuhan Ruijian Pharmaceutical Technology Co., Ltd., a leading enterprise in the development of drugs for chemically induced adult cells, has announced the completion of its Pre-A financing round, raising tens of millions of yuan. This round was jointly invested by Renfu Industry Fund and Huafang Capital. The funds will be used to complete the safety evaluation and Investigational New Drug (IND) application for NouvNeu001, Ruijian Pharmaceutical’s first Parkinson’s disease pipeline candidate.

Wuhan Ruijian Pharmaceutical Technology Co., Ltd. is a novel platform-based cell therapy company dedicated to addressing unmet medical needs. Leveraging its proprietary library of small-molecule inducers and real-time live-cell reporting platform, the company has developed multiple pipelines of cell therapies based on chemically induced adult cell regeneration, covering areas such as neurodegenerative diseases, metabolic disorders, and rare diseases. Founded in August 2017 by returning scholars from the University of Cambridge, UK, the two founders each possess over ten years of successful overseas experience in the development of cell therapies and nucleic acid therapeutics, respectively. Since its establishment, Wuhan Ruijian has received support from various programs, including the “Startup Program for Overseas Returnees” by the Chinese Ministry of Human Resources and Social Security, the UK EPSRC Industrial Innovation Project, Hubei Province’s “Hundred Talents Program,” Wuhan City’s Industrial Leading Talent Program, and the “3551 Talent Program.” The company has been granted multiple invention patents in the field of chemical induction, and its medical team’s achievements were awarded the Second Prize for Scientific and Technological Progress in Hubei Province in 2019.

In January 2019, Wuhan Ruijian completed its angel financing round, led by Huafang Capital and co-invested by the Optics Valley Talent Fund. Currently, Wuhan Ruijian has established a GMP-compliant seed cell bank, a library of over one hundred small-molecule inducers, an iPSC/ESC induction and differentiation system, and a robust non-stem cell conversion platform. Its lead candidate, NouvNeu001, has demonstrated remarkable therapeutic efficacy in primate models of Parkinson’s disease and completed pilot-scale production. The proceeds from this financing round will be primarily allocated to advancing safety evaluations and Investigational New Drug (IND) application preparations for this pipeline, while comprehensively enhancing Wuhan Ruijian Pharmaceutical’s overall capabilities and industrialization progress. This round of financing also underscores the strong confidence of existing investors in the company’s development.

Huafang Capital is an investment fund focused on the biopharmaceutical and broader healthcare sector, with a particular emphasis on biopharmaceuticals, high-end medical devices, healthcare services, and healthcare informatization. It has already completed investments in multiple leading companies across various niche segments. The core team of Huafang Capital has many years of deep experience in the pharmaceutical industry, possessing profound knowledge and understanding of the pharmaceutical and healthcare sectors. They offer unique insights into industry development trends, project innovation and differentiation, and the capability building of entrepreneurial teams. Huafang Capital empowers its portfolio companies through industrial resources to facilitate their rapid growth. Huafang Capital was also an angel investor in Wuhan Ruijian Pharmaceutical. Ruijian Pharmaceutical’s pipeline has been advancing rapidly and steadily, demonstrating the team’s forward-looking approach to innovative therapies and strong R&D capabilities.

Humanwell Healthcare established a professional VC/PE management institution in 2013 and initiated the creation of multiple pharmaceutical industry funds. Leveraging its advantages as an industrial investor with over a decade of experience in investing in and operating pharmaceutical enterprises, the company has assembled a team of seasoned investment and research professionals. This team identifies high-value “investment targets” through extensive and high-quality screening. By providing management expertise and importing resources, Humanwell Healthcare not only accelerates the growth of its portfolio companies but also expands business operations in key development areas, thereby strengthening its position as a globally competitive international pharmaceutical enterprise.